Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

被引：0
|
作者：
Terpos, Evangelos
Badros, Ashraf
Popat, Rakesh
Rodriguez-Otero, Paula
Farooq, Asim
Jeng, Bennie
Esposti, Simona Degli
Lewis, Eric
Gupta, Ira
Opalinska, Joanna
Palumbo, Antonio
Trudel, Suzanne
机构：
[1] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[3] Univ Coll London Hosp, NHS Fdn Trust, London, England
[4] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Navarra, Spain
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[7] UCL Inst Ophthalmol, London, England
[8] GlaxoSmithKline, Res Triangle Pk, NC USA
[9] GlaxoSmithKline, Upper Providence, PA USA
[10] GlaxoSmithKline, Zug, Switzerland
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8033
引用
收藏
页数：4
相关论文
共 34 条
  • [21] DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Popat, Rakesh
    Lonial, Sagar
    Voorhees, Peter M.
    Degli Esposti, Simona
    Gupta, Ira
    Opalinska, Joanna
    Sapra, Sandhya
    Gorsh, Boris
    He, Zangdong
    Kleinman, David M.
    Schaumberg, Debra
    Loubert, Angely
    Meunier, Juliette
    Regnault, Antoine
    Eliason, Laurie
    BLOOD, 2020, 136
  • [22] Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
    Hultcrantz, Malin
    Anderson, Larry D., Jr.
    Anwer, Faiz
    Gasparetto, Cristina
    Kocoglu, Mehmet H.
    Lichtman, Eben I.
    Mo, Clifton
    Niesvizky, Ruben
    Lewis, Eric
    Li, Hong
    Paul, Sofia
    Petrone, Stephanie
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S440
  • [23] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
    Hungria, Vania T. M.
    Weisel, Katja
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Kouri, Fotini
    Liboon, John
    Brawley, Chris
    Lewis, Eric
    Tubel, Gabriela
    Li, Mary
    McKeown, Astrid
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [24] Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 DREAMM-5 Platform Sub-Study 3
    Callander, Natalie S.
    Richardson, Paul G.
    Hus, Marek
    Ribrag, Vincent
    Lopez, Joaquin Martinez
    Kim, Kihyun
    Lee, Jae Hoon
    Dimopoulos, Meletis
    Schjesvold, Fredrik
    Facon, Thierry
    Jo, Jae-Cheol
    Min, Chang-Ki
    Mielnik, Michal
    Cheng, Shinta
    Smith, L. Mary
    Breitbach, Caroline J.
    Brawley, Chris
    Sembhi, Harjeet
    LaMacchia, John
    Hakim, Shawn
    Kremer, Brandon E.
    Grosicki, Sebastian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S507 - S508
  • [25] DREAMM-5 platform trial: Belantamab Mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Richardson, P. G.
    Trudel, S.
    Callander, N.
    Nooka, A.
    Song, K.
    Uttervall, K.
    Minnema, M. C.
    Rodriguez-Otero, P.
    Struemper, H.
    Yeakey, A.
    de Oca, Montes R.
    Smith, L. M.
    Jackson, N.
    Kaisermann, M.
    Im, E.
    Basile, F. G.
    Ahlers, C. M.
    Holkova, B.
    Gupta, I
    Kremer, B. E.
    Quach, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 205
  • [26] Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3
    Leypoldt, L.
    Callander, N. S.
    Richardson, P. G.
    Hus, M.
    Ribrag, V.
    Lopez, J. M.
    Kim, K.
    Lee, J. H.
    Dimopoulos, M. A.
    Schjesvold, F.
    Facon, T.
    Jo, J. -C.
    Min, C. -K.
    Mielnik, M.
    Cheng, S.
    Smith, L. M.
    Breitbach, C. J.
    Brawley, C.
    Sembhi, H.
    LaMacchia, J.
    Grosicki, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 176 - 177
  • [27] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
    Hungria, Vania
    Weisel, Katja
    Currie, Brooke
    Perera, Sue
    Sule, Neal
    He, Wei
    Davy, Katherine
    McKeown, Astrid
    Sapra, Sandhya
    Nelsen, Linda
    Li, Mary
    Barale, Sophie
    Boyle, Julia
    McPoyle, Kaytlyn
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
  • [28] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Moreau, Philippe
    Usmani, Saad Zafar
    van de Donk, Niels W. C. J.
    Garfall, Alfred L.
    Delforge, Michel
    Rocafiguera, Albert Oriol
    Nooka, Ajay K.
    Rosinol, Laura
    Bahlis, Nizar J.
    Rodriguez-Otero, Paula
    Martin, Thomas G.
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Slavcev, Mary
    Smit, Jennifer
    Londhe, Anil
    Krishnan, Amrita Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    BLOOD, 2020, 136
  • [30] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
    Kortuem, M.
    Trudel, S.
    Cohen, A. D.
    Richardson, P. G.
    Lonial, S.
    Opalinska, J. B.
    Gupta, I
    Byrne, J.
    Zhi, E.
    Baron, J.
    Morgan, L.
    Voorhees, P. M.
    Popat, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
1234